Pharmaceutical companies

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Pharmaceutical companies, Health care, Companies, Regulus Therapeutics, PTC Therapeutics

NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m.

Key Points: 
  • NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
  • Zentalis has licensed ZN-c3, ZN-c5 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
Wednesday, August 4, 2021
Perrigo, Companies, Pharmaceutical companies

A generic product, ivermectin cream, 1% was launched by partner Perrigo in June 2021.

Key Points: 
  • A generic product, ivermectin cream, 1% was launched by partner Perrigo in June 2021.
  • Financial Resultsfor theSecond QuarterEndedJune30, 2021
    Revenue for the second quarter of 2021 was$0.9 million.
  • Sol-Gelreported a loss of$8.0 millionfor the second quarter of 2021 compared to loss of$7.1 millionfor the same period in 2020.
  • These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives.

Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case

Retrieved on: 
Wednesday, August 4, 2021
Endo International, Civil procedure, Civil law, Settlement, Opioid, Legal case, Law, Pharmaceutical companies, Companies

DUBLIN, Aug. 4, 2021 /PRNewswire/ --Endo Internationalplc(NASDAQ: ENDP) today announced that its wholly-owned subsidiariesEndo Health Solutions Inc.andEndo Pharmaceuticals Inc.(collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned asStaubus, et al.

Key Points: 
  • DUBLIN, Aug. 4, 2021 /PRNewswire/ --Endo Internationalplc(NASDAQ: ENDP) today announced that its wholly-owned subsidiariesEndo Health Solutions Inc.andEndo Pharmaceuticals Inc.(collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned asStaubus, et al.
  • The Staubus case involved claims by nine counties in eastern Tennessee, eighteen cities and towns within those counties and one individual plaintiff.
  • The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo, and the settlement value should not be extrapolated to any other opioid-related cases or claims.
  • All forward-looking statements in this press release reflectEndo'scurrent expectations of future events based on information available toEndoas of the date of this press release.

Endo Announces Execution of Definitive Settlement Agreement and Release Resolving Tennessee State Court Case

Retrieved on: 
Wednesday, August 4, 2021
Endo International, Civil procedure, Civil law, Settlement, Opioid, Legal case, Law, Pharmaceutical companies, Companies

DUBLIN, Aug. 4, 2021 /PRNewswire/ --Endo Internationalplc(NASDAQ: ENDP) today announced that its wholly-owned subsidiariesEndo Health Solutions Inc.andEndo Pharmaceuticals Inc.(collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned asStaubus, et al.

Key Points: 
  • DUBLIN, Aug. 4, 2021 /PRNewswire/ --Endo Internationalplc(NASDAQ: ENDP) today announced that its wholly-owned subsidiariesEndo Health Solutions Inc.andEndo Pharmaceuticals Inc.(collectively, "Endo") have executed a definitive Settlement Agreement and Release (the "Settlement Agreement") resolving an opioid-related case originally captioned asStaubus, et al.
  • The Staubus case involved claims by nine counties in eastern Tennessee, eighteen cities and towns within those counties and one individual plaintiff.
  • The settlement includes no admission of wrongdoing, fault or liability of any kind by Endo, and the settlement value should not be extrapolated to any other opioid-related cases or claims.
  • All forward-looking statements in this press release reflectEndo'scurrent expectations of future events based on information available toEndoas of the date of this press release.

DGAP-News: DEFENCE THERAPEUTICS SIGNS AN AGREEMENT WITH BIOPHARMA EXCELLENCE A PHARMALEX GMBH COMPANY, TO MAXIMIZE AND STRATEGIZE THE DEVELOPMENT OF ITS ACCUMTM PLATFORM AND CLINICAL TRIALS

Retrieved on: 
Wednesday, August 4, 2021
Defence Therapeutics, Companies, Pharmaceutical companies

DEFENCE THERAPEUTICS SIGNS AN AGREEMENT WITH BIOPHARMA EXCELLENCE A PHARMALEX GMBH COMPANY, TO MAXIMIZE AND STRATEGIZE THE DEVELOPMENT OF ITS ACCUMTM PLATFORM AND CLINICAL TRIALS

Key Points: 
  • DEFENCE THERAPEUTICS SIGNS AN AGREEMENT WITH BIOPHARMA EXCELLENCE A PHARMALEX GMBH COMPANY, TO MAXIMIZE AND STRATEGIZE THE DEVELOPMENT OF ITS ACCUMTM PLATFORM AND CLINICAL TRIALS
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS SIGNS AN AGREEMENT WITH BIOPHARMA EXCELLENCE A PHARMALEX GMBH COMPANY, TO MAXIMIZE AND STRATEGIZE THE DEVELOPMENT OF ITS ACCUMTM PLATFORM AND CLINICAL TRIALS
    Vancouver, BC, Canada, August 4th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is pleased to announce the agreement with the German renowned pharmaceutical consulting and advisory company, Pharmalex GmbH, through Biopharma Excellence.
  • Dr.Michael Pfleiderer of Biopharma Excellence will advise and guide Defence through both strategy and regulatory affairs, related mainly on integrated drugs/products developments, manufacturing, control, clinical trials, FDA IND , and potential strategic pharma partners.
  • Dr. Michael Pfleiderer of Biopharma Excellence will be the Lead Scientist to achieve the mandate.

Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline

Retrieved on: 
Wednesday, August 4, 2021
Research, Technology, Other Technology, Clinical trials, Biotechnology, Radiology, Pharmaceutical, Health, Science, Other Science, Synaffix, Pharmaceutical companies, Kyowa Hakko Kirin, Companies, Health care, Sutro Biopharma, Kyowa Kirin, Synaffix B.V., KYOWA KIRIN, SYNAFFIX B.V.

View the full release here: https://www.businesswire.com/news/home/20210804005099/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210804005099/en/
    In exchange for the license signature fee, Synaffix will initially provide target-specific rights to its proprietary ADC technologies, enabling Kyowa Kirin to evaluate two of its antibodies as proprietary ADC therapeutic candidates within its pipeline.
  • Kyowa Kirin may expand the deal with additional ADC targets at a later point in time.
  • Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform.
  • The business model of Synaffix is target-specific technology out-licensing, as exemplified through its existing deals with six premier ADC drug developers.

BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Geography of the United States, BeiGene, Hopewell, NEW JERSEY, United States, Pharmaceutical companies

In the interim, BeiGene plans to rent space nearby and begin to hire immediately.

Key Points: 
  • In the interim, BeiGene plans to rent space nearby and begin to hire immediately.
  • We are proud to be building our campus in New Jersey, and were grateful for the warm welcome BeiGene has received across the state, said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene.
  • We are excited to connect more with the deep talent pool in the region as we plan to diversify and further expand.
  • We hope that BeiGene and its new manufacturing and R&D campus in Hopewell will help bring that day closer to reality, said New Jersey Governor Phil Murphy.

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration

Retrieved on: 
Monday, August 2, 2021
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Life sciences, Industry economics), Pharmaceutical companies, Takeda Pharmaceutical Company, Green Cross, Takeda Oncology, Gaucher disease (GD), CANbridge Pharmaceuticals Inc., GAUCHER DISEASE (GD), CANBRIDGE PHARMACEUTICALS INC.

CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, announced that the Investigational New Drug (IND) application for CAN103 has been accepted by the Chinese National Medical Products Administration (NMPA).

Key Points: 
  • CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, announced that the Investigational New Drug (IND) application for CAN103 has been accepted by the Chinese National Medical Products Administration (NMPA).
  • Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc., who also serves as the Deputy Director General of the China Alliance for Rare Disease (CHARD).
  • CANbridge is committed to developing a sustainable solution to addressing Gaucher in China, where patients are significantly underserved, and potentially worldwide.
  • CANbridge Pharmaceuticals Inc. is a China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

Retrieved on: 
Friday, July 30, 2021
Pharmaceutical companies, Lexicon Pharmaceuticals, Schering-Plough, Schering, Companies, Pharmaceutical industry

THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021.

Key Points: 
  • THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021.
  • Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having previously built global medical organizations at three separate companies.
  • Prior to the merger, he held a variety of medical and commercial management positions with Schering-Plough, including group vice president, head of global medical affairs.
  • We are very pleased to have Dr. Granowitz join Lexicon as our chief medical officer, said Lonnel Coats, Lexicons president and chief executive officer.

Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis

Retrieved on: 
Wednesday, July 28, 2021
Public policy, Government, Healthcare reform, Pharmaceutical, Health, Teva Pharmaceuticals, Pharmaceutical companies, Life sciences, Industry economics), the Teva Economic Impact Report, Matrix Global Advisors, Teva, THE TEVA ECONOMIC IMPACT REPORT, MATRIX GLOBAL ADVISORS, TEVA

In addition, the Companys economic activity supported nearly 250,000 jobs and contributed $52 billion to economic output across 15 countries.

Key Points: 
  • In addition, the Companys economic activity supported nearly 250,000 jobs and contributed $52 billion to economic output across 15 countries.
  • During 2020, Teva continued to provide access to quality affordable medicines, despite the challenges brought by the pandemic, said Kre Schultz, President and CEO of Teva.
  • The Companys economic activity also supported more than 57,000 U.S. jobs and contributed $15.7 billion in economic output in the United States.
  • Across 9 major markets in Europe, Teva saved healthcare systems $9.6 billion in 2020, supported more than 100,000 jobs and contributed $29.5 billion to economic output.